Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat

Key Points

• Maze reported Q4 EPS of ‑$0.65 vs. consensus ‑$0.73, beating estimates and uplifting the stock about 5.5% intraday.
• Topline Phase 2 HORIZON data for MZE829 showed a 35.6% mean uACR reduction at week 12 (61.8% in the FSGS subgroup), which the company says is the first clinical proof‑of‑concept in broad APOL1‑mediated kidney disease and will be advanced to a pivotal program.
• While analysts have raised price targets and the company reports a ~$360M cash runway into 2028, heavy insider selling and sharp intraday swings underscore elevated volatility and near‑term risk.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares shot up 5.5% during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $33.44 and last traded at $33.4720. 464,133 shares traded hands during mid-day trading, a decline of 28% from the average session volume of 640,987 shares. The stock had previously closed at $31.73.

The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Positive Phase 2 HORIZON topline: MZE829 produced a 35.6% mean uACR reduction at week 12 (50% of patients >30% reduction); especially strong 61.8% uACR reduction in the FSGS subgroup. Company says this is the first clinical proof‑of‑concept in broad APOL1‑mediated kidney disease and plans to advance MZE829 to a pivotal program. Maze Announces Positive Topline Data
• Positive Sentiment: Analyst upgrades/price‑target increases: HC Wainwright raised its target sharply (to $110) and BTIG reaffirmed buy with a $46 target — signals some analysts view the program as high‑value despite volatility. Benzinga Coverage of Analyst Actions
• Positive Sentiment: Board strengthening: Maze added Neil Kumar (BridgeBio founder/CEO) to its board, which may boost strategic/partnering credibility. TipRanks: Neil Kumar Joins Board
• Neutral Sentiment: Solid balance sheet & quarterly results: Maze reported Q4/2025 results with an EPS beat (‑$0.65 vs. consensus ‑$0.73) and said it has ~$360M cash runway into 2028 — provides runway for pivotal development. Maze Reports Q4 and FY2025 Results
• Negative Sentiment: Market reaction—mixed read of data and rapid profit‑taking: despite positive topline, several outlets reported the readout as "mixed" for the broader market (claims of market‑share loss), triggering a sharp intraday sell‑off and high volatility as investors parsed subgroup vs. overall results. BioSpace: Mixed Midstage Data Coverage
• Negative Sentiment: Insider sale/exercise: an executive reported selling 15,000 shares via option exercise (≈$736K) in mid‑March — an event some investors interpret as near‑term selling pressure or opportunistic monetization. Fool: Insider Sale Report
• Negative Sentiment: High intraday divergence in headlines: outlets noted both a 22% pre‑market surge on the news and later steep declines — this reflects fast shifting sentiment and technical selling/positioning rather than new clinical failures. Investing.com: Stock Reaction Coverage

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MAZE shares. Truist Financial assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, March 17th. They issued a "buy" rating and a $68.00 price objective on the stock. BTIG Research reissued a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 7th. Wedbush lifted their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the stock an "outperform" rating in a research note on Monday, March 16th. Finally, HC Wainwright upped their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $64.11.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, SVP Amy Bachrodt sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company's stock, valued at approximately $526,119.70. This represents a 43.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 245,000 shares of company stock worth $10,504,792.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics during the fourth quarter worth about $43,000. California State Teachers Retirement System raised its position in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after buying an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares in the last quarter.

Maze Therapeutics Trading Up 7.3%

The company has a 50 day simple moving average of $45.98 and a 200 day simple moving average of $37.55. The stock has a market cap of $1.64 billion, a P/E ratio of -1.64 and a beta of 4.47.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.